Articles

Assessment of knowledge, attitude and practice of fixed-dose combinations amongst attending physicians and residents: a cross-sectional evaluation

Dhyuti Gupta, Prithpal Singh Matreja, Shilpa Patrick, Meenu Thomas, Pooja Agarwal, Preeti Singh

Article Type

Original Research

Published

This study is a cross-sectional survey of physicians employed in a tertiary care teaching hospital to comprehend their level of knowledge regarding fixed-dose combinations (FDCs) as well as their attitude towards analysing the rationality of and their practice of prescribing these FDCs.

Read more

Cost-effectiveness of albumin in the treatment of decompensated cirrhosis in resource-limited healthcare settings

Irsan Hasan, Ignatia Sinta Murti, Putut Bayupurnama, Kemal Fariz Kalista, Christina Hill-Zabala, Dennis Kananda, Elisabet Viayna

Article Type

Original Research

Published

This study aims to assess the cost-effectiveness of human albumin in patients with cirrhosis with spontaneous bacterial peritonitis, hepatorenal syndrome or ascites requiring large-volume paracentesis in the Indonesian healthcare system as a representative of a resource-limited setting.

Read more

Three once-weekly intra-articular injections of Hylan G-F 20 significantly improve pain relief compared with placebo in patients with chronic idiopathic knee osteoarthritis: a single-centre, evaluator-blinded and patient-blinded, randomized controlled trial

Michael Langworthy, Peter Lascarides, Wilson Ngai, Kevin Steele, Yili Huang

Article Type

Original Research

Published

This study was conducted to determine the efficacy and safety of three once-weekly injections of intra-articular Hylan G-F 20 in patients with chronic knee osteoarthritis over 26 weeks. It was hypothesized that Hylan G-F 20 would provide significant pain relief with no increased safety risk compared with IA saline (placebo).

Read more

Corrigendum: Vulnerable period in heart failure: a window of opportunity for the optimization of treatment – a statement by Mexican experts

José Antonio Magaña Serrano, José Angel Cigarroa López, Adolfo Chávez Mendoza, Juan Betuel Ivey-Miranda, Genaro Hiram Mendoza Zavala, Luis Olmos Domínguez, Sergio Armando Chávez Leal, José Ernesto Pombo Bartelt, Eduardo Heberto Herrera-Garza, Gerardo Mercado Leal, Rodolfo Parra Michel, Luisa Fernanda Aguilera Mora, Patricia Lenny Nuriulu Escobar

Article Type

Corrigendum

Published

The authors wish to make the following corrections to their article: Magaña Serrano JA, Cigarroa López JA, Chávez Mendoza A, Ivey-Miranda JB, Mendoza Zavala GH, Olmos Domínguez L, Chávez Leal SA, Pombo Bartelt JE, Herrera-Garza EH, Mercado Leal G, Parra Michel R, Aguilera Mora LF, Nuriulu Escobar PL. Corrigendum: Vulnerable period in heart failure: a window of opportunity for the optimization of treatment – a statement by Mexican experts. Drugs Context. 2024;13:2023-8-1. https://doi.org/10.7573/dic.2023-8-1

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.